Finding may help doctors pinpoint likelihood of kidney transplant failure

September 25, 2013 by Amy Norton, Healthday Reporter
Finding may help doctors pinpoint likelihood of kidney transplant failure
Patients with a particular antibody response were much more likely to run into trouble, researchers report.

(HealthDay)—Kidney transplant patients who develop a specific type of antibody response may be at particular risk of having the organ fail within a few years, a new study suggests.

Experts said the results could help pinpoint those who are at the highest of a —and possibly aid in finding a good donor organ for some .

"This is a very exciting paper," Dr. Jacqueline Lappin, a at Scott & White Healthcare in Temple, Texas, said of the study, which appears in the Sept. 26 issue of the New England Journal of Medicine.

Lappin, who was not involved in the research, said the findings give insight into the specific type of immune response that is dangerous to a donor organ. And that could have implications for patients both before and after a , she added.

For the study, French researchers followed 1,016 patients who received donor kidneys at two Paris transplant centers. They wanted to see whether patients who developed a particular type of antibody against the donor organ would be at increased risk of having the transplant fail in the next few years.

The research focused on so-called anti-HLA . HLAs are proteins on the surface of white blood cells and other tissues; if a kidney donor's HLAs do not fully match a recipient's, the recipient's immune system will develop anti-HLA antibodies.

But while those antibodies may attack and severely injure the donor kidney in some patients, they may do little to no damage in others—suggesting not all anti-HLA antibodies are bad news.

"What we've been grappling with is, what is a 'relevant' antibody?" Lappin said.

Based on the new findings, the anti-HLA antibodies that are a problem can be distinguished by whether they bind to an immune system protein called C1q. The 77 patients with C1q-binding antibodies were at much higher risk of having the donor kidney fail, according to the researchers.

Only 54 percent of those patients saw their kidney "survive" for five years, vs. about 94 percent of patients with either no anti-HLA antibodies or anti-HLA antibodies that did not bind to C1q.

An antibody's ability to bind to C1q is key because it activates a part of the called the complement system, which helps antibodies fight foreign invaders.

The new findings suggest that measuring the "complement-binding" capacity of anti-HLA antibodies could help spot patients at particular risk of a donor kidney loss, according to the research team, led by Dr. Alexandre Loupy of the French national research institute INSERM.

The results are "intriguing" and "certainly advance the field," said Dr. Lorraine Racusen, a pathology professor at Johns Hopkins University in Baltimore.

But there are still questions to answer before such testing comes into routine use, according to Racusen, who wrote an editorial published with the study.

A big one is whether C1q antibodies respond to therapy, and whether that will actually improve how patients fare, she said. There are potential ways to lower patients' antibody levels: One, Racusen said, is to filter them from the blood in a process called plasmapheresis; another is treatment with medications like intravenous immunoglobulin.

Racusen said that measuring this particular characteristic of patients' anti-HLA antibodies "adds some refinement" to gauging the risk of kidney loss. But, she added, "is this something that people need to implement now? No, I don't think so."

Lappin said she thinks the "most exciting" potential use could be in the period where doctors are trying to find a good donor-recipient match—particularly for "sensitized" patients.

About 30 percent of people who need a donor kidney are considered sensitized, which means they have a high level of anti-HLA antibodies. They have those antibodies as a result of past exposure to foreign tissue—either from a previous kidney transplant, or from another source, like a blood transfusion or pregnancy.

It's estimated that sensitized patients wait three to four times longer for a compatible kidney from a deceased donor, vs. non-sensitized patients.

When a potential donor kidney is found, doctors perform a "cross-match" test, which involves mixing a blood sample from the recipient with blood cells from the donor. If the result is "positive," that means the patient has anti-HLA antibodies against that donor's tissue.

In those cases, patients may be able to have the anti-HLA antibodies removed, in what doctors call "desensitization." Even after that process, though, the can still be rejected, and the cost of desensitization ranges from $20,000 to $30,000—which may or may not be covered by insurance.

But Lappin said the new results present the possibility that if patients' antibodies are not of the C1q-binding variety, the donor kidney could still be suitable.

"That could potentially give sensitized patients more options," she said.

In the United States, almost 98,000 people are currently on the waiting list to get a , according to the Organ Procurement and Transplantation Network.

Explore further: Low levels of donor-specific antibodies increase risks for transplant recipients

More information: The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more on kidney transplants.

Related Stories

Low levels of donor-specific antibodies increase risks for transplant recipients

November 15, 2012
Kidney transplant recipients who have even very low levels of preformed antibodies directed against a donated kidney have a significantly increased risk of organ rejection and kidney failure, according to a study appearing ...

Promising breakthrough for transplant patients

February 27, 2013
A team led by Dr. Marie-Josée Hébert from the University of Montreal Hospital Research Centre (CRCHUM) has discovered a new cause of organ rejection in some kidney transplant patients. Her team has identified a new class ...

Cancerous cells from donor kidney linked to recipient skin cancer

August 27, 2013
Patients that receive kidney transplants have an increased risk of an invasive form of skin cancer. It is unclear if donor tissue contributes to cancer formation.

Antibody response may lead to narrowed arteries and organ rejection

April 14, 2011
Kidney transplant recipients who develop antibodies in response to receiving new organs can develop accelerated arteriosclerosis, or narrowing of the arteries that supply blood to the kidney, according to a study appearing ...

Recommended for you

World's first child hand transplant a 'success'

July 19, 2017
The first child in the world to undergo a double hand transplant is now able to write, feed and dress himself, doctors said Tuesday, declaring the ground-breaking operation a success after 18 months.

Knee surgery—have we been doing it wrong?

July 18, 2017
A team of University at Buffalo medical doctors have published a study that challenges a surgical practice used for decades during arthroscopic knee surgery.

New tools help surgeons find liver tumors, not nick blood vessels

July 17, 2017
The liver is a particularly squishy, slippery organ, prone to shifting both deadly tumors and life-preserving blood vessels by inches between the time they're discovered on a CT scan and when the patient is lying on an operating ...

Researchers discover indicator of lung transplant rejection

July 13, 2017
Research by scientists at Dignity Health St. Joseph's Hospital and Medical Center's Norton Thoracic Institute was published in the July 12, 2017 issue of Science Translational Medicine titled "Zbtb7a induction in alveolar ...

New device could make closing surgical incisions a cinch

July 7, 2017
Like many surgeons, Dr. Jason Spector is often faced with the challenge of securely closing the abdominal wall without injuring the intestines. If the process goes awry, there can be serious consequences for patients, including ...

Success with first 20 patients undergoing minimally invasive pancreatic transplant surgery

June 29, 2017
Surgeons at Johns Hopkins Medicine report that their first series of a minimally invasive procedure to treat chronic pancreas disease, known as severe pancreatitis, resulted in shorter hospital stays, less need for opioids ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.